Matisse Capital Myovant Sciences Ltd. Transaction History

Matisse Capital

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 07, 2020	SELL	$6.55 - $14.76 $214,512 - $483,390	-32,750 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$4.2 - $19.21 $137,550 - $629,127	32,750 New	32,750 $508,000
Q4 2018 Jan 18, 2019	SELL	$15.01 - $25.2 $228,902 - $384,300	-15,250 Closed	0 $0
Q2 2018 Jul 13, 2018	BUY	$19.2 - $25.14 $292,800 - $383,385	15,250 New	15,250 $349,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Matisse Capital, based on Form 13F filings with the SEC.

Stay updated on Matisse Capital with notifications on news.